Gyre Therapeutics, Inc. cash flow to debt ratio of 107.56% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Gyre Therapeutics, Inc.'s free cash flow has increased -97.34% from $-6.77M last year to $-180.00K, signaling increasing performance

Gyre Therapeutics, Inc.'s debt to equity ratio is 0.03, which means that the company's assets are healthy financed, signaling financial stability.

Gyre Therapeutics, Inc.'s debt has increased relative to shareholder equity from 0.03 last year to 0.03 today, signaling weakened financials

Gyre Therapeutics, Inc. has a net cash position, so leverage is healthy.

Gyre Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Gyre Therapeutics, Inc.'s profit margin has decreased (227.06%) in the last year from 11.43% to -14.52%, signaling decreasing performance

Gyre Therapeutics, Inc.'s short-term assets of $102.37M exceed its short-term liabilities of $18.29M

Gyre Therapeutics, Inc.'s return on assets of -8.70% is lower than the 5.00% threshold, indicating inefficient asset utilization

Gyre Therapeutics, Inc.'s return on equity of -15.77%, is lower than 15.00%, indicating bad performance

Gyre Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Gyre Therapeutics, Inc. had positive net income in 3 out of 5 years, indicating stable and consistent earnings

Gyre Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Gyre Therapeutics, Inc. has negative free cash flow, indicating cash burn

Gyre Therapeutics, Inc.'s yearly earnings has decreased 58.40% since last year from $12.09M to $5.03M, signaling decreasing performance

Gyre Therapeutics, Inc.'s yearly revenue has increased 10.24% since last year from $105.76M to $116.59M, signaling increasing performance

ROIC -9.69% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Gyre Therapeutics, Inc.'s 3-year revenue CAGR of 4.46% is positive, indicating growing revenue over the past 3 years

Gyre Therapeutics, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Gyre Therapeutics, Inc. had positive ROE in 3 out of 5 years, indicating consistent and reliable returns on equity

Gyre Therapeutics, Inc. is overvalued relative to its fair value price of 0.37 based on Discounted Cash Flow model

Gyre Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Gyre Therapeutics, Inc. is overvalued relative to its fair value price of 1.47 based on EBITDA multiple model

Gyre Therapeutics, Inc. has an EV/EBITDA ratio of 41.15x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Gyre Therapeutics, Inc. is overvalued relative to its fair value price of 1.50 based on Earnings Fair Value model

Gyre Therapeutics, Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Gyre Therapeutics, Inc. has a price-to-book ratio of 4.10x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Gyre Therapeutics, Inc. has a price-to-sales ratio of 5.66x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue